Q1 Earnings Estimate for TNYA Issued By Lifesci Capital

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) – Equities researchers at Lifesci Capital issued their Q1 2025 earnings per share (EPS) estimates for shares of Tenaya Therapeutics in a report released on Tuesday, March 11th. Lifesci Capital analyst C. Jubinville expects that the company will post earnings per share of ($0.15) for the quarter. The consensus estimate for Tenaya Therapeutics’ current full-year earnings is ($1.35) per share. Lifesci Capital also issued estimates for Tenaya Therapeutics’ Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.22) EPS and FY2025 earnings at ($0.73) EPS.

Tenaya Therapeutics (NASDAQ:TNYA) last issued its earnings results on Monday, March 17th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.04.

A number of other research firms have also weighed in on TNYA. Chardan Capital reiterated a “buy” rating and set a $18.00 price objective on shares of Tenaya Therapeutics in a research note on Wednesday, December 18th. HC Wainwright reduced their price objective on Tenaya Therapeutics from $18.00 to $5.00 and set a “buy” rating for the company in a research note on Tuesday. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $13.00.

Tenaya Therapeutics Price Performance

Shares of TNYA stock opened at $0.54 on Wednesday. The business has a fifty day moving average of $1.11 and a 200 day moving average of $1.85. The firm has a market capitalization of $42.78 million, a price-to-earnings ratio of -0.38 and a beta of 2.83. Tenaya Therapeutics has a 1 year low of $0.39 and a 1 year high of $5.73.

Insider Activity

In other Tenaya Therapeutics news, major shareholder Group Gp Lp Column III bought 35,714,284 shares of the company’s stock in a transaction dated Wednesday, March 5th. The shares were purchased at an average cost of $0.70 per share, for a total transaction of $24,999,998.80. Following the transaction, the insider now directly owns 49,313,559 shares of the company’s stock, valued at approximately $34,519,491.30. The trade was a 262.62 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders have sold 19,621 shares of company stock worth $10,595 in the last ninety days. Company insiders own 32.76% of the company’s stock.

Institutional Investors Weigh In On Tenaya Therapeutics

A number of institutional investors have recently modified their holdings of TNYA. Synovus Financial Corp acquired a new stake in Tenaya Therapeutics in the 3rd quarter worth about $28,000. Woodline Partners LP acquired a new stake in Tenaya Therapeutics in the 4th quarter worth about $28,000. Commerce Bank acquired a new stake in Tenaya Therapeutics in the 4th quarter worth about $29,000. Mariner LLC acquired a new stake in Tenaya Therapeutics in the 4th quarter worth about $30,000. Finally, Ground Swell Capital LLC acquired a new stake in Tenaya Therapeutics in the 4th quarter worth about $32,000. 90.54% of the stock is currently owned by institutional investors and hedge funds.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.